Tag Archives: Biogen Idec

Elan Announces Further Unlocking of Value To Benefit Shareholders

By Business Wirevia The Motley Fool

Filed under:

Elan Announces Further Unlocking of Value To Benefit Shareholders

  • Unique Cash Dividend For Shareholders
  • Dividend Calculated As a Percentage of Tysabri Royalty Payments To Elan
  • Initial Percentage To Be Paid to Shareholders is 20% of That Royalty
  • Establishes Direct Link Between Shareholders And Tysabri Cash Flow
  • Novel Construct Crystalizes Further Shareholder Benefit Post Tysabri Restructuring

DUBLIN–(BUSINESS WIRE)– The Board of Elan Corporation, plc (NYS: ELN) (the Company) has approved the decision to initiate a unique cash dividend policy enabling its shareholders to benefit directly from the long term cash flow generated by Tysabri.

The dividend program will be directly linked to Tysabri market performance calculated as a percentage of the Tysabri royalty paid to Elan from Biogen Idec as a result of the recently announced Tysabri restructuring. The initial percentage to be paid out directly to shareholders is 20 % of those royalties.

There is no cap to the dividend cash payments that will be generated from this direct link between shareholders’ equity and the long term cash flow of Tysabri. This dividend structure gives shareholders the right to enjoy unlimited participation in the upside from the Tysabri sales increase which we anticipate for the future.

The Company expects to pay these cash dividends to its shareholders in twice-yearly instalments. The first dividend is expected to be paid in the fourth quarter of 2013, subject to the closing of the recently announced Tysabri restructuring. Payment of the dividends will be made in accordance with applicable law, including, where applicable, shareholder approval.

According to the restructured Tysabri collaboration, Elan will receive 12% royalties on in-market sales of Tysabri in the first year from closing and thereafter 18% royalties on …read more
Source: FULL ARTICLE at DailyFinance

The Fight Over This Biotech's Cash

By Brian Orelli, The Motley Fool

Elan was nice enough to give us a little more detail on what it plans to do with the $3.25 million that the biotech stands to get from Biogen Idec in exchange for turning over its rights to multiple sclerosis drug Tysabri and accepting a royalty on sales of the drug.

But just a little bit.

On Friday, Elan said it’ll split the money between “strategic initiatives” — essentially buying assets or drugs to help the company diversify — and a $1 billion share repurchase. Elan…

The Fight Over This Biotech’s Cash originally appeared on DailyFinance.com on 2013-02-25T14:44:00Z.

Permalink | Email this | Comments

…read more
Source: FULL ARTICLE at DailyFinance

Biogen Idec ALS Drug Fails

By Matthew Herper, Forbes Staff Deciding to bet on dexpramipexole, an experimental drug for ALS, was one of the first bets made by Biogen Idec chief executive George Scangos when he arrived at the company. Now the medicine has failed, and rather definitively, according to the company:

Today Biogen Idec (BIIB) reported top-line results […]

Source: FULL ARTICLE at Forbes Latest